Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Strangvac, a vaccine against equine Strangles, released for sale in Sweden
Stockholm, March 23, 2022 – Intervacc announces today that the first batch of Strangvac®, a vaccine against equine Strangles, has been released for sale in Sweden. “Strangvac® has now been released and is in stock at our logistics partner in Sweden. The next...The European Medicines Agency extends the shelf life of the antigens used in Strangvac to 28 months
Stockholm, March 9, 2022 – The European Medicines Agency has today, after reviewing stability data, approved the extension of the shelf life of the antigens in Strangvac to 28 months. The manufacturing of Strangvac®, a vaccine against the highly contagious...Year-end report January – December 2021
The period in summary January 1 – December 31, 2021 The European Commission granted in August a Marketing Authorisation for Strangvac within the European Union. During September the Veterinary Medicines Directorate (VMD) of the United Kingdom also granted a Marketing...Intervacc applies for a Permit for Sale and Distribution of Strangvac in the U.S.
Stockholm, February 16, 2022 – Intervacc AB (publ) announces that the Company’s application for a Permit for Sale and Distribution of Strangvac® in the U.S. has been submitted to the U.S. Department of Agriculture (USDA). Intervacc is seeking approval for...Intervacc has applied for supplementary protection certificates for Strangvac in key European markets
Stockholm, February 1, 2022 – The European patent for Strangvac®, a vaccine against equine strangles, is approved and in force until May 2031. Pending the approval of the supplementary protection certificates, the protection in Great Britain, Sweden, the...Nyhetstjänster
